- Home
- CHA vs BBIO Comparison
CHA vs BBIO Comparison
Compare CHA & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHA
- BBIO
- Stock Information
- Founded
- CHA 2017
- BBIO 2015
- Country
- CHA China
- BBIO United States
- Employees
- CHA N/A
- BBIO N/A
- Industry
- CHA
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CHA
- BBIO Health Care
- Exchange
- CHA NYSE
- BBIO Nasdaq
- Market Cap
- CHA 5.5B
- BBIO 6.7B
- IPO Year
- CHA 2025
- BBIO 2019
- Fundamental
- Price
- CHA $28.01
- BBIO $34.25
- Analyst Decision
- CHA
- BBIO Strong Buy
- Analyst Count
- CHA 0
- BBIO 12
- Target Price
- CHA N/A
- BBIO $57.09
- AVG Volume (30 Days)
- CHA 1.1M
- BBIO 2.9M
- Earning Date
- CHA 05-30-2025
- BBIO 04-29-2025
- Dividend Yield
- CHA N/A
- BBIO N/A
- EPS Growth
- CHA 186.29
- BBIO N/A
- EPS
- CHA 1.95
- BBIO N/A
- Revenue
- CHA $1,699,604,333.00
- BBIO $127,415,000.00
- Revenue This Year
- CHA N/A
- BBIO $89.10
- Revenue Next Year
- CHA N/A
- BBIO $57.07
- P/E Ratio
- CHA $14.34
- BBIO N/A
- Revenue Growth
- CHA 167.35
- BBIO N/A
- 52 Week Low
- CHA $27.21
- BBIO $21.62
- 52 Week High
- CHA $41.80
- BBIO $39.54
- Technical
- Relative Strength Index (RSI)
- CHA N/A
- BBIO 50.58
- Support Level
- CHA N/A
- BBIO $31.77
- Resistance Level
- CHA N/A
- BBIO $33.93
- Average True Range (ATR)
- CHA 0.00
- BBIO 1.28
- MACD
- CHA 0.00
- BBIO -0.09
- Stochastic Oscillator
- CHA 0.00
- BBIO 57.14
About CHA CHAGEE HOLDINGS LTD SPON ADS EACH R SPON ADS EACH REP 1 CL A
Chagee Holdings Ltd is a premium tea drinks brand. It is engaged in the sales of freshly-made tea drinks, related raw materials, packaging, teahouse equipment and other supplies in China.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.